Elsevier established a free COVID-19 resource center in January 2020, offering English and Mandarin information on the virus. The center is hosted on Elsevier Connect, and Elsevier grants permission to freely share its research in PubMed Central and other repositories for research reuse. The article discusses combining antiviral and anti-inflammatory treatments for COVID-19. It highlights the use of Baricitinib, a JAK inhibitor, which can inhibit clathrin-mediated endocytosis and potentially reduce SARS-CoV-2 infection. Baricitinib is effective against various viruses and has anti-inflammatory properties. It is well-tolerated, with minimal side effects. Other JAK inhibitors like Ruxolitinib and Fedratinib are less effective in inhibiting viral entry. Baricitinib's high affinity for NAKs, its anti-inflammatory effects, and favorable pharmacokinetic properties make it a promising candidate. It can be combined with direct-acting antivirals like Lopinavir, Ritonavir, and Remdesivir to reduce viral replication and inflammation. The study shows how AI-driven knowledge graphs can accelerate drug development. The authors disclose potential conflicts of interest. The research is part of ongoing efforts to combat the pandemic.Elsevier established a free COVID-19 resource center in January 2020, offering English and Mandarin information on the virus. The center is hosted on Elsevier Connect, and Elsevier grants permission to freely share its research in PubMed Central and other repositories for research reuse. The article discusses combining antiviral and anti-inflammatory treatments for COVID-19. It highlights the use of Baricitinib, a JAK inhibitor, which can inhibit clathrin-mediated endocytosis and potentially reduce SARS-CoV-2 infection. Baricitinib is effective against various viruses and has anti-inflammatory properties. It is well-tolerated, with minimal side effects. Other JAK inhibitors like Ruxolitinib and Fedratinib are less effective in inhibiting viral entry. Baricitinib's high affinity for NAKs, its anti-inflammatory effects, and favorable pharmacokinetic properties make it a promising candidate. It can be combined with direct-acting antivirals like Lopinavir, Ritonavir, and Remdesivir to reduce viral replication and inflammation. The study shows how AI-driven knowledge graphs can accelerate drug development. The authors disclose potential conflicts of interest. The research is part of ongoing efforts to combat the pandemic.